News, musings and commentary on dietary supplements & pharmaceutical law issues, technology, and litigation.
Lawyers for consumers and injured people.(No advice on this blog, though)
Thursday, April 26, 2018
Nuplazid in the News
The Food and Drug Administration (FDA) is re-examining the safety of a new drug after reports that it has potentially caused serious side effects and numerous deaths.
The agency confirmed to The Hill it is “conducting an evaluation of available information” about Nuplazid, a drug approved in 2016 to treat delusions and hallucinations associated with Parkinson’s disease psychosis.
During a House hearing about FDA’s budget last week, Rep. Rosa DeLauro(D-Conn.) pressed FDA Commissioner Scott Gottlieb to answer why the drug was still on the market, even though there were 600 reported deaths associated with the drug in 2017.